Product
anti-CD20 Antibody + Bortezomib
1 clinical trial
2 indications
Indication
Autoimmune Hemolytic AnemiaClinical trial
An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic AnemiaStatus: Completed, Estimated PCD: 2024-03-01